American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 362-365 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Medical Economic Perspective

  • Joshua T. Cohen, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Joshua T. Cohen, PhD, Institute for Clinical Research and Health Policy Studies, Tufts-New England Medical Center, Boston, MA 02111.
    • ,
  • Peter J. Neumann, ScD

References 

  1. Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernan MA. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA. 2007;297:1667–1674
  2. Szczech LA, Klassen PS, Chua B, et al. Associations between CMS’s Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int. 2006;69:2094–2100
  3. Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: Provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis. 2007;49:135–142
  4. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders; 2006;
  5. Coyne DW. Use of epoetin in chronic renal failure. JAMA. 2007;297:1713–1716
  6. Devereaux PJ, Schunemann HJ, Ravindran N, et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: A systematic review and meta-analysis. JAMA. 2002;288:2449–2457
  7. Garg PP, Frick KD, Diener-West M, Powe NR. Effect of the ownership of dialysis facilities on patients’ survival and referral for transplantation. N Engl J Med. 1999;341:1653–1660
  8. Woolhandler S, Himmelstein DU. The high costs of for-profit care. CMAJ. 2007;170:1814–1815
  9. Carlson MD, Gallo WT, Bradley EH. Ownership status and patterns of care in hospice: Results from the National Home and Hospice Care Survey. Med Care. 2004;42:432–438
  10. Devereaux PJ, Choi PT, Lacchetti C, et al. A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ. 2002;166:1399–1406
  11. Harrington C, Woolhandler S, Mullan J, Carrillo H, Himmelstein DU. Does investor ownership of nursing homes compromise the quality of care?. Am J Public Health. 2001;91:1452–1455
  12. Cotter D, Thamer M, Narasimhan K, et al. Translating epoetin research into practice: The role of government and the use of scientific evidence. Health Aff (Millwood). 2006;25:1249–1259
  13. Centers for Medicare and Medicaid Services. CMS Manual System. Pub 100-04 Medicare Claims Processing. Transmittal 1043. Change Request 5251. 8-25-2006. Available at: http://www.cms.hhs.gov/Transmittals/Downloads/R1043CP.pdf. Accessed June 1, 2007
  14. de LG, Powe NR, Griffiths RI, et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care. 1994;32:130–140
  15. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm. Accessed January 18, 2007
  16. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis. 2004;44:866–876
  17. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2006;CD003967
  18. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64:295–304
  19. Kalantar-Zadeh K, McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JD. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis. 2003;42:761–773
  20. Blake GJ, Ridker PM, Kuntz KM. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med. 2003;114:485–494
  21. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology. 2003;228:515–522

PII: S0272-6386(07)01038-4

doi: 10.1053/j.ajkd.2007.07.009

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 362-365 , September 2007

Article Tools

* Image Usage & Resolution